Results 171 to 180 of about 6,428 (233)
Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry. [PDF]
Rheumatology (Oxford)Hum RM, Lilleker JB, Lamb JA, Oldroyd AGS, Wang G, Wedderburn LR, Wedderburn LR, Diederichsen LP, Schmidt J, Danieli MG, Oakley P, Griger Z, Nguyen Thi Phuong T, Kodishala C, Vazquez-Del Mercado M, Andersson H, De Paepe B, De Bleecker JL, Maurer B, McCann L, Pipitone N, McHugh N, New RP, Ollier WE, Krogh NS, Vencovsky J, Lundberg IE, Chinoy H, MYONET Registry. +28 moreeuropepmc +1 more sourceEfficacy of pharmacological interventions and therapeutic exercises for rheumatoid arthritis: a systematic review and meta-analysis. [PDF]
Front PharmacolAdeyemi T, Chukwuike VI, Oladimeji MA, Ahwinahwi US, Ayeni VA, Abdullahi AA, Isah A, Ayamolowo LB, Okeke OP, Abodunrin O, Akinsolu F, Sobande OO. +11 moreeuropepmc +1 more sourceBiological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis. [PDF]
RMD OpenKarpouzas GA, Ormseth SR, van Riel PLCM, Gonzalez-Gay MA, Corrales A, Rantapää-Dahlqvist S, Sfikakis PP, Dessein P, Tsang L, Hitchon C, El-Gabalawy H, Pascual-Ramos V, Contreras-Yáñez I, Colunga-Pedraza IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Semb AG, Misra DP, Hauge EM, Kitas G. +19 moreeuropepmc +1 more sourceLong-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. [PDF]
Br J Gen PractWu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B, CTT Collaboration secretariat CTT Collaboration trialists: A to Z trial (phase Z) AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study)ALERT (Assessment of Lescol in Renal Transplantation)ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus)AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events)CARDS (Collaborative Atorvastatin Diabetes Study)CARE (Cholesterol And Recurrent Events Study)CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)4D (Die Deutsche Diabetes Dialyse Studie)GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico) Heart Failure and Prevention trialsHOPE-3HPS (Heart Protection Study)IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid-lowering)JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease)LIPS (Lescol Intervention Prevention Study)Post-CABG (Post-Coronary Artery Bypass Graft Study)PROSPER (Prospective Study of Pravastatin in the Elderly at Risk)PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy)SEARCH (Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine)SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels)4S (Scandinavian Simvastatin Survival Study)TNT (Treating to New Targets)WOSCOPS (West of Scotland Coronary Prevention Study)Other CTT Collaboration members. +13 moreeuropepmc +1 more source
